Table 3.
Combination therapy: Cisplatin plus fluoropyrimidines for advanced gastric cancer in Japan.
| Treatment schedule | No. pts. | Response rate | Median survival (months) | Author (year) | |||
|---|---|---|---|---|---|---|---|
| Cisplatin | IV | 20 mg/m2/d | days 1–5 | 40 | 43% | 9 | Ohtsu39 (1994) |
| 5-FU | CI | 800 mg/m2/d | days 1–5, q4w k | ||||
| Cisplatin | IV | 80 mg/m2/d | day 5 days 1–5,15–18, q4wk | 44 | 50% | 9.1 | Koizumi37 (1993) |
| 5′ -DFUR | po | 1,400 mg/m2/d | |||||
| Cisplatin | IV | 80 mg/m2/d | day 8 | 41 | 51% | 8.6 | Sato38 (2000) |
| UFT | po | 350 mg/m2/d | days 1–21, q4wk | ||||
| Cisplatin* | IV | 60 mg/m2/d | day 8 | 25 | 76% | 12.8 | Koizumi41 (2003) |
| S-1 | po | 80 mg/m2/d | days 1–21, q4wk | ||||
Abbreviations: CI = continuous infusion; 5-FU = 5-fluorouracil; IV = intravenous; po = orally.
*
Phase I/II study.